William Blair Estimates Hologic's Q3 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Analysts at William Blair increased their Q3 2025 earnings per share estimates for Hologic in a research note issued to investors on Thursday, February 6th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will post earnings of $1.12 per share for the quarter, up from their previous estimate of $1.10. William Blair has a "Outperform" rating on the stock. The consensus estimate for Hologic's current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic's Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Other analysts have also recently issued research reports about the company. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research report on Thursday, November 14th. JPMorgan Chase & Co. lifted their target price on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They issued a "peer perform" rating for the company. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $85.77.

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $0.77 during trading on Friday, hitting $64.47. The company had a trading volume of 1,084,524 shares, compared to its average volume of 2,548,522. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. Hologic has a 12 month low of $63.62 and a 12 month high of $84.67. The stock has a 50 day simple moving average of $72.06 and a 200 day simple moving average of $77.67. The firm has a market capitalization of $14.55 billion, a P/E ratio of 20.30, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently modified their holdings of HOLX. Sanctuary Advisors LLC acquired a new stake in shares of Hologic in the second quarter valued at $1,212,000. Czech National Bank grew its stake in shares of Hologic by 6.4% in the third quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider's stock valued at $3,854,000 after buying an additional 2,843 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock valued at $312,000 after buying an additional 582 shares in the last quarter. Marcum Wealth LLC acquired a new stake in shares of Hologic in the third quarter valued at $202,000. Finally, Wedmont Private Capital boosted its holdings in Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock valued at $361,000 after purchasing an additional 162 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.